Vnitr Lek 2024, 70(8):E15-E18 | DOI: 10.36290/vnl.2024.105

Microbiome and atherosclerosis

Pavol Fülöp1, Marianna Vachalcová2, Barbora Sepešiová2, Denisa Harvanová3, Katarîna Šoltys4, Gabriel Valočik2
1 Interná klinika UPJŠ LF a Nemocnice AGEL Košice-Šaca, a. s.
2 I. kardiologická klinika UPJŠ LF a VÚSCH, a. s., Košice
3 Združená tkanivová banka UPJŠ LF a UNLP v Košiciach
4 Prîrodovedecká fakulta, UK v Bratislave

Atherosclerosis is a major cause of cardiovascular diseases and significantly contributes to global mortality. An increasing body of evidence suggests that the gut microbiome may play a key role in the pathogenesis of this disease. The gut microbiome consists of trillions of microorganisms that not only support digestion and metabolism but also influence the host's immune response. Alterations in the composition of the gut microbiome have been associated with various chronic diseases, including obesity, diabetes, and atherosclerosis. This article provides a brief overview of the gut microbiome composition in patients with coronary artery disease and summarizes the potential underlying mechanisms influencing the development of atherosclerosis. The composition of the gut microbiome in patients with atherosclerosis differs from that in healthy individuals. Identifying and understanding these differences offers new opportunities for the diagnosis and treatment of atherosclerosis.

Keywords: atherosclerosis, gut microbiome, microbiology, coronary artery disease, progression of atherosclerosis.

Accepted: December 13, 2024; Published: December 18, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fülöp P, Vachalcová M, Sepešiová B, Harvanová D, Šoltys K, Valočik G. Microbiome and atherosclerosis. Vnitr Lek. 2024;70(8):E15-18. doi: 10.36290/vnl.2024.105.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. Go to original source... Go to PubMed...
    2. Rinninella E, Raoul P, Cintoni M, et al. What Is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms 2019, 7, 14. Go to original source... Go to PubMed...
    3. Sonnenburg JL, Bäckhed, F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016;535:56-64 Go to original source... Go to PubMed...
    4. Olvera-Rosales LB, Cruz-Guerrero AE, Ramírez-Moreno E, et al. Impact of the Gut Microbiota Balance on the Health-Disease Relationship: The Importance of Consuming Probiotics and Prebiotics. Foods. 2021;10(6):1261. Go to original source... Go to PubMed...
    5. Bäckhed F, Fraser CM, Ringel Y, et al. Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe. 2012;12:611-22. Go to original source... Go to PubMed...
    6. Jonsson A, Bäckhed F. Role of gut microbiota in atherosclerosis. Nat Rev Cardiol. 2017;14:79-87. Go to original source... Go to PubMed...
    7. Liu Q, Li YC, Song X, et al. Both gut microbiota and cytokines act to atherosclerosis in ApoE-/- mice. Microb Pathog. 2019;103827. Go to original source... Go to PubMed...
    8. Zhu Q, Gao R, Zhang Y, et al. Dysbiosis signatures of gut microbiota in coronary artery disease. Physiol Genomics. 2018. Go to original source... Go to PubMed...
    9. Yvan-Charvet L, Welch C, Pagler TA, et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation. 2008;118(18):1837-1847. Go to original source... Go to PubMed...
    10. Chacón MR, Lozano-Bartolomé J, Portero-Otín M, et al. The gut mycobiome composition is linked to carotid atherosclerosis. Benef Microbes. 2018;9:185-98. Go to original source... Go to PubMed...
    11. Kozarov E. Bacterial invasion of vascular cell types: vascular infectology and atherogenesis. Future. Cardiol. 2012;8(1):123-138. Go to original source... Go to PubMed...
    12. Liu X, Xie Z, Sun M, Wang X, Li J, Cui J, et al. Plasma trimethylamine N- oxide is associated with vulnerable plaque characteristics in CAD patients as assessed by optical coherence tomography. Int J Cardiol. 2018;265:18- 23. Go to original source... Go to PubMed...
    13. Koren O, Spor A, Felin J, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A. 2011;108 Suppl 1(Suppl 1):4592-4598. Go to original source... Go to PubMed...
    14. Karlsson FH, Fåk F, Nookaew I, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3:1245. Go to original source... Go to PubMed...
    15. Choroszy M, Litwinowicz K, Bednarz R, et al. Human Gut Microbiota in Coronary Artery Disease: A Systematic Review and Meta-Analysis. Metabolites. 2022;12(12):1165. Go to original source... Go to PubMed...
    16. Kazemian N, Mahmoudi M, Halperin F. et al. Gut Microbiota and Cardiovascular Disease: Opportunities and Challenges. Microbiome 2020, 8, 36. Go to original source... Go to PubMed...
    17. Kriaa A, Bourgin M, Potiron, A, et al. Microbial Impact on Cholesterol and Bile Acid Metabolism: Current Status and Future Prospects. J. Lipid Res. 2019;60:323-332. Go to original source... Go to PubMed...
    18. Wexler A.G, Goodman A.L. An Insider's Perspective: Bacteroides as a Window into the Microbiome. Nat. Microbiol. 2017;2:17026. Go to original source... Go to PubMed...
    19. Yoshida N, Yamashita T, Kishino S, et al. A Possible Beneficial Effect of Bacteroides on Faecal Lipopolysaccharide Activity and Cardiovascular Diseases. Sci. Rep. 2020;10:13009. Go to original source... Go to PubMed...
    20. Yoshida N, Emoto T, Yamashita T, et al. Bacteroides Vulgatus and Bacteroides Dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis. Circulation 2018;138:2486-2498. Go to original source... Go to PubMed...
    21. Sasaki N, Takeuchi H, Kitano S, et al. Dynamic analysis of Porphyromonas gingivalis invasion into blood capillaries during the infection process in host tissues using a vascularized three-dimensional human gingival model. Biomater Sci. 2021;9(19):6574-6583. Go to original source... Go to PubMed...
    22. Grigorieva I. Atherosclerosis and trimethylamine-N-oxide - the gut microbiota potential. Russian Journal of Cardiology. 2022. Go to original source...
    23. Gaetti-jardim E, Marcelino SL, Feitosa AC, et al. Detection of bacteria in atheromatous plaques of patients with coronary artery disease by polymerase chain reaction. Anaerobe. 2009;15(3):89-92.
    24. Hansen GM, Greve JH, Greve ML. Pseudomonas aeruginosa microcolonies in coronary thrombi. Eur J Clin Microbiol Infect Dis. 2016. Go to original source... Go to PubMed...
    25. Tungland B. Dysbiosis of the microbiota: therapeutic strategies utilizing dietary modification, pro- and prebiotics and fecal transplant therapies in promoting normal balance and local GI functions. In: Elsevier; 2018:381-419. doi:10.1016/B978-0-12-814649-1.00009-0. Go to original source...
    26. Gao M, Heng X, Jin J, Chu W. Gypenoside XLIX ameliorate high-fat diet-induced atherosclerosis via regulating intestinal microbiota, alleviating inflammatory response and restraining oxidative stress in ApoE-/- mice. Pharmaceuticals. 2022. Go to original source...
    27. Yan N, Wang L, Li Y, et al. Metformin intervention ameliorates AS in ApoE-/- mice through restoring gut dysbiosis and anti-inflammation. PLoS ONE. 2021. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.